Here are 1-2 brief analogies to describe Veradermics:

1. Like a pharmaceutical 'Tesla' for hair loss, taking a known hair growth ingredient (minoxidil) and re-engineering it into a superior, convenient, and safer oral treatment.
2. Imagine the 'iPhone' of hair loss treatments: Veradermics is developing a premium, convenient oral solution that aims to dramatically improve user satisfaction over current options.

• VDPHL01: An investigational oral, extended-release (ER) formulation of minoxidil designed as a non-hormonal treatment for pattern hair loss (PHL) in both men and women.

Veradermics (MANE) sells primarily to individuals. The company is developing VDPHL01, an oral, non-hormonal treatment for pattern hair loss (PHL), which, if approved, will be a prescribed therapy for patients. Its commercial strategy involves direct-to-consumer (DTC) advertising and physician education to reach these end-users.

The up to three categories of customers Veradermics aims to serve are:

1. Men with Pattern Hair Loss (PHL): Specifically, men suffering from mild-to-moderate PHL, for whom VDPHL01 is designed to offer a more effective, convenient, and safe oral treatment option compared to existing therapies.
2. Women with Pattern Hair Loss (PHL): Women affected by mild-to-moderate PHL, who currently have limited FDA-approved oral treatment options and often face tolerability issues with existing hormonal or topical treatments.
3. Patients seeking improved treatment options for PHL: This category includes both men and women who are dissatisfied with the shortcomings of current PHL treatments (e.g., slow onset, inconsistent results, insufficient hair density, tolerability issues, inconvenience) or are currently untreated but are motivated to address their hair loss with a potentially transformative and well-tolerated oral therapy.

Reid Waldman, MD, Chief Executive Officer and Board Member

Dr. Waldman is a co-founder of Veradermics, established in October 2019. As CEO, he has led the company through significant equity financings, including a $150 million Series C round, and advanced VDPHL01, their lead asset, into Phase 3 trials. He is a board-certified dermatologist with over a decade of clinical experience. Before founding Veradermics, Dr. Waldman was an active researcher, authoring more than 100 publications and a textbook. He has received the American Academy of Dermatology's “Excellence in Patient Care” award and was recognized in Forbes 30 under 30 list.

Dominic Carrano, CPA, Chief Financial Officer and Treasurer

Mr. Carrano brings over 15 years of experience in financial leadership, technical accounting, and strategic planning within the life sciences sector, overseeing Veradermics' financial strategy and operations. Prior to his role as CFO, he served as the Vice President of Finance at Veradermics. His previous experience includes finance leadership positions at Rallybio and Alexion, and he began his career at Deloitte.

Tim Durso, MD, Chief Technical Officer

Dr. Durso also serves as President of Veradermics, where he spearheads the company's research and development efforts. He is a board-certified dermatologist with over 10 years of clinical experience, and he played a key role in progressing VDPHL01 from its conceptual stage to clinical testing. Dr. Durso is recognized for his expertise in dermatology drug and device innovation. He previously served as the Chief of Dermatology at Malcolm Grow Medical Clinics.

Mark Neumann, Chief Commercial and Strategy Officer

Mr. Neumann possesses over three decades of leadership experience in biopharmaceutical commercialization. He previously held the position of Executive Vice President and Chief Commercial Officer at Intra-Cellular Therapies (ITCI), where he established the commercial function and successfully launched CAPLYTA®. Mr. Neumann was instrumental in ITCI's acquisition by Johnson & Johnson in 2025 for approximately $14.6 billion. His career also includes senior commercial roles at Amgen and Bristol-Myers Squibb.

Michael Greco, JD, General Counsel

Mr. Greco serves as the General Counsel for Veradermics. His background includes in-house leadership roles and practicing as a corporate and transactional attorney at Bingham McCutchen LLP and Wiggin and Dana LLP. He has also held prior senior legal positions at Rallybio, SpringWorks, and Alexion.

The addressable market for Veradermics' main product, VDPHL01, for PHL treatments for men and women in the U.S. is approximately $9 billion annually.

Expected Drivers of Future Revenue Growth for Veradermics (MANE)

1. Successful FDA Approval and Commercial Launch of VDPHL01 for Male Pattern Hair Loss: Veradermics anticipates topline data from its pivotal Phase 2/3 trial in male patients in the first half of 2026 and from its confirmatory Phase 3 trial in male patients in the second half of 2026. This is expected to lead to a New Drug Application (NDA) submission and subsequent regulatory approval, making VDPHL01 available for a significant segment of the pattern hair loss market.
2. Expansion into the Female Pattern Hair Loss Market: The company is conducting a registrational-directed Phase 2/3 trial for female patients with pattern hair loss. Securing FDA approval for this indication, potentially through a supplemental NDA or simultaneously with male patients, would significantly expand the addressable patient population and unlock a substantial portion of the estimated $9 billion annual U.S. commercial opportunity.
3. Market Penetration through a Differentiated Product Profile: VDPHL01 is positioned as a potentially first-in-class oral, non-hormonal FDA-approved therapy for pattern hair loss, offering attributes such as speed of hair growth, consistency, intensity, and a favorable safety profile compared to existing options. This differentiated profile is expected to address high unmet needs and patient dissatisfaction, driving significant adoption in a large and motivated patient population.
4. Execution of a Comprehensive Multi-Channel Commercialization Strategy: In anticipation of potential NDA submission, Veradermics is developing a robust commercialization plan. This strategy will integrate patient identification, physician education, direct-to-consumer (DTC) advertising, social media, and telehealth engagement. Effective execution of these commercial pillars, particularly a dermatology-focused field force and DTC advertising, is crucial to driving patient awareness, demand, and ultimately, revenue growth for VDPHL01.